CorVista Health Showcases High-Sensitivity Noninvasive Detection of CAD, Including INOCA, at ACC.26
CorVista Health Unveils Machine Learning–Driven Noninvasive Approach to Detect Cardiac Ischemia at ACC.26 CorVista Health has announced promising new clinical data supporting a novel, noninvasive diagnostic approach for detecting cardiac…
Merck’s Enlicitide Decanoate Shows Superior LDL-C Reduction at Eight Weeks vs. Oral Non-Statins
Merck Presents Phase 3 CORALreef AddOn Data for Enlicitide, Highlighting Strong LDL-C Reductions and Potential as First Oral PCSK9 Inhibitor Merck has unveiled compelling late-breaking results from its Phase 3…
LEO Pharma Showcases 12-Month Real-World Data on Tralokinumab at AAD 2026
LEO Pharma Showcases New Real-World Data on Tralokinumab at AAD 2026, Highlighting Benefits Across Diverse Atopic Dermatitis Populations LEO Pharma has presented new post-hoc analyses from its ongoing TRACE study,…
ACC.26 Data Highlight Benefits of Vutrisiran in ATTR-CM and Underscore Zilebesiran’s Potential in Hypertension Management
Alnylam Highlights New Cardiovascular Data at ACC.26, Reinforcing Potential of RNAi Therapies in ATTR-CM and Hypertension Alnylam Pharmaceuticals has unveiled a comprehensive set of new clinical and real-world findings from…
Meiji Seika Pharma Backs Centivax to Advance Next-Generation Universal Vaccine Platform
Meiji Seika Pharma Invests in Centivax to Advance Universal Vaccine Innovation and Broaden Global Infectious Disease Preparedness Meiji Seika Pharma Co., Ltd., a leading Japanese pharmaceutical company with a long-standing…
Biocytogen Licenses RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform to Taisho Pharmaceutical
Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based…
PepGen Reports Phase 2 FREEDOM2 Low-Dose Cohort Results Showing Strong Safety and Efficacy Signals
PepGen Reports Encouraging Phase 2 Data for PGN-EDODM1 in Myotonic Dystrophy Type 1, Advances Higher-Dose Cohort in FREEDOM2 Trial PepGen Inc., a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide…
DiaMedica Therapeutics Announces Full-Year 2025 Financial Results and Key Business Highlights
DiaMedica Therapeutics Reports 2025 Financial Results and Advances Clinical Pipeline in Preeclampsia and Acute Ischemic Stroke DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious…
Emmaus Life Sciences Announces Annual Financial Results and Business Update
Emmaus Life Sciences Announces Annual Financial Performance Update Emmaus Life Sciences Reports 2025 Financial Results, Navigates Revenue Pressure with Cost Discipline and Strategic Shift Emmaus Life Sciences, Inc., a commercial-stage…
Roche Introduces cobas MPX-E Assay, a 4-in-1 Donor Screening Test to Enhance Global Blood Safety
Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro…
Incyte Highlights Positive 54-Week Povorcitinib Data at AAD 2026
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical…